Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 20;22(22):12522.
doi: 10.3390/ijms222212522.

Recent Findings Related to Cardiomyopathy and Genetics

Takanobu Yamada  1 , Seitaro Nomura  1
Affiliations
Review

Recent Findings Related to Cardiomyopathy and Genetics

Takanobu Yamada et al. Int J Mol Sci. .

Abstract

With the development and advancement of next-generation sequencing (NGS), genetic analysis is becoming more accessible. High-throughput genetic studies using NGS have contributed to unraveling the association between cardiomyopathy and genetic background, as is the case with many other diseases. Rare variants have been shown to play major roles in the pathogenesis of cardiomyopathy, which was empirically recognized as a monogenic disease, and it has been elucidated that the clinical course of cardiomyopathy varies depending on the causative genes. These findings were not limited to dilated and hypertrophic cardiomyopathy; similar trends were reported one after another for peripartum cardiomyopathy (PPCM), cancer therapy-related cardiac dysfunction (CTRCD), and alcoholic cardiomyopathy (ACM). In addition, as the association between clinical phenotypes and the causative genes becomes clearer, progress is being made in elucidating the mechanisms and developing novel therapeutic agents. Recently, it has been suggested that not only rare variants but also common variants contribute to the development of cardiomyopathy. Cardiomyopathy and genetics are approaching a new era, which is summarized here in this overview.

Keywords: cardiomyopathy; dilated cardiomyopathy (DCM); genetics; genotype–phenotype correlations; hypertrophic cardiomyopathy (HCM); pathogenesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Elliott P., Andersson B., Arbustini E., Bilinska Z., Cecchi F., Charron P., Dubourg O., Kü U., Maisch B., Mckenna W.J., et al. Classification of the Cardiomyopathies: A Position Statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2008;29:270–276. doi: 10.1093/eurheartj/ehm342. - DOI - PubMed
    1. Semsarian C., Ingles J., Maron M.S., Maron B.J. New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy. J. Am. Coll. Cardiol. 2015;65:1249–1254. doi: 10.1016/j.jacc.2015.01.019. - DOI - PubMed
    1. Maron M.S., Hellawell J.L., Lucove J.C., Farzaneh-Far R., Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am. J. Cardiol. 2016;117:1651–1654. doi: 10.1016/j.amjcard.2016.02.044. - DOI - PubMed
    1. Weintraub R.G., Semsarian C., Macdonald P. Dilated Cardiomyopathy. Lancet. 2017;390:400–414. doi: 10.1016/S0140-6736(16)31713-5. - DOI - PubMed
    1. Hershberger R.E., Hedges D.J., Morales A. Dilated Cardiomyopathy: The Complexity of a Diverse Genetic Architecture. Nat. Rev. Cardiol. 2013;10:531–547. doi: 10.1038/nrcardio.2013.105. - DOI - PubMed

MeSH terms